NCT01034657View on ClinicalTrials.gov

LBH589 Alone or in Combination With Erythropoietin Stimulating Agents (ESA) in Patients With Low or Int-1 Risk Myelodysplastic Syndromes (MDS)

PHASE2TerminatedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

August 31, 2012

Study Completion Date

August 31, 2012

Conditions
Myelodysplastic Syndrome (MDS)
Interventions
DRUG

LBH589

LBH589 was supplied at dose strengths of 5 mg or 20 mg hard gelatin capsules.

DRUG

Epoetin Alfa

Epoetin alfa was supplied as 10000 IU/1 mL in a ready-to-use syringe.

Trial Locations (12)

12203

Novartis Investigative Site, Berlin

30625

Novartis Investigative Site, Hanover

37075

Novartis Investigative Site, Göttingen

40225

Novartis Investigative Site, Düsseldorf

47166

Novartis Investigative Site, Duisburg

53105

Novartis Investigative Site, Bonn

60590

Novartis Investigative Site, Frankfurt

68305

Novartis Investigative Site, Mannheim

81675

Novartis Investigative Site, München

89081

Novartis Investigative Site, Ulm

01307

Novartis Investigative Site, Dresden

04103

Novartis Investigative Site, Leipzig

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY